14001-67-3 Usage
General Description
5-Bromo-2-(methylthio)pyrimidine is a chemical compound with the molecular formula C5H5BrN2S. It is a pyrimidine derivative with a bromine atom and a methylthio group attached to the pyrimidine ring. 5-BROMO-2-(METHYLTHIO)PYRIMIDINE is commonly used in the pharmaceutical industry as a building block in the synthesis of various biologically active molecules, including pharmaceutical drugs. It is also utilized as an intermediate in the manufacturing of agrochemicals, dyes, and other fine chemicals. Additionally, 5-Bromo-2-(methylthio)pyrimidine has potential applications in organic synthesis and research, making it a valuable compound in the field of chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 14001-67-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,0,0 and 1 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 14001-67:
(7*1)+(6*4)+(5*0)+(4*0)+(3*1)+(2*6)+(1*7)=53
53 % 10 = 3
So 14001-67-3 is a valid CAS Registry Number.
InChI:InChI=1/C5H5BrN2S/c1-9-5-7-2-4(6)3-8-5/h2-3H,1H3
14001-67-3Relevant articles and documents
METALLOENZYME INHIBITOR COMPOUNDS
-
Page/Page column 137, (2018/09/28)
Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
Lee, Junwon,Kim, Jong Yup,Choi, Jungsub,Lee, Sung-Han,Kim, Jeongmin,Lee, Jinhwa
experimental part, p. 7046 - 7049 (2010/12/25)
Novel C-aryl glucoside SGLT2 inhibitors containing pyrimidine motif were designed and synthesized for biological evaluation. Among the compounds assayed, pyrimidine containing methylthio moiety 11g demonstrated the best in vitro inhibitory activity against SGLT2 in this series to date (IC50 = 10.7 nM).
NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES
-
Page/Page column 23-24, (2008/06/13)
The invention provides compounds of formula (I), wherein R1 and R2 are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
